These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 12788888)
21. Induction of male sexual behavior in the rat by 7 alpha-methyl-19-nortestosterone, an androgen that does not undergo 5 alpha-reduction. Moralí G; Lemus AE; Munguía R; Arteaga M; Pérez-Palacios G; Sundaram K; Kumar N; Bardin CW Biol Reprod; 1993 Sep; 49(3):577-81. PubMed ID: 8399852 [TBL] [Abstract][Full Text] [Related]
22. Comparison of 7α-methyl-19-nortestosterone effectiveness alone or combined with progestins on androgen receptor mediated-transactivation. García-Becerra R; Ordaz-Rosado D; Noé G; Chávez B; Cooney AJ; Larrea F Reproduction; 2012 Feb; 143(2):211-9. PubMed ID: 22065861 [TBL] [Abstract][Full Text] [Related]
23. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049 [TBL] [Abstract][Full Text] [Related]
24. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. Amory JK; Watts NB; Easley KA; Sutton PR; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL J Clin Endocrinol Metab; 2004 Feb; 89(2):503-10. PubMed ID: 14764753 [TBL] [Abstract][Full Text] [Related]
25. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. Grinspoon S; Corcoran C; Lee K; Burrows B; Hubbard J; Katznelson L; Walsh M; Guccione A; Cannan J; Heller H; Basgoz N; Klibanski A J Clin Endocrinol Metab; 1996 Nov; 81(11):4051-8. PubMed ID: 8923860 [TBL] [Abstract][Full Text] [Related]
26. Long-term effects of dimethandrolone 17β-undecanoate and 11β-methyl-19-nortestosterone 17β-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. Attardi BJ; Marck BT; Matsumoto AM; Koduri S; Hild SA J Androl; 2011; 32(2):183-92. PubMed ID: 20798389 [TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. Raynaud JP; Gardette J; Rollet J; Legros JJ BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Shao TC; Li HL; Kasper S; Matusik R; Ittmann M; Cunningham GR Prostate; 2006 Mar; 66(4):369-76. PubMed ID: 16302273 [TBL] [Abstract][Full Text] [Related]
29. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N; J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892 [TBL] [Abstract][Full Text] [Related]
30. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475 [TBL] [Abstract][Full Text] [Related]
31. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. Leder BZ; Rohrer JL; Rubin SD; Gallo J; Longcope C J Clin Endocrinol Metab; 2004 Mar; 89(3):1174-80. PubMed ID: 15001605 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma. Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152 [TBL] [Abstract][Full Text] [Related]
33. Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy. Sasagawa I; Nakada T; Kazama T; Satomi S; Terada T; Katayama T Int Urol Nephrol; 1990; 22(3):279-84. PubMed ID: 2210985 [TBL] [Abstract][Full Text] [Related]
34. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. Zitzmann M; Depenbusch M; Gromoll J; Nieschlag E J Clin Endocrinol Metab; 2003 May; 88(5):2049-54. PubMed ID: 12727953 [TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD J Androl; 2002; 23(6):922-6. PubMed ID: 12399540 [TBL] [Abstract][Full Text] [Related]
36. Use of biomarkers to assess tissue specific androgen adequacy: defining male hypogonadism. Jarow JP; Troiani J; McNellis D; Wiederhorn R; Fang G; Handelsman H J Urol; 2013 Feb; 189(2):633-7. PubMed ID: 23260553 [TBL] [Abstract][Full Text] [Related]
37. An aged rat model of partial androgen deficiency: prevention of both loss of bone and lean body mass by low-dose androgen replacement. Vanderschueren D; Vandenput L; Boonen S; Van Herck E; Swinnen JV; Bouillon R Endocrinology; 2000 May; 141(5):1642-7. PubMed ID: 10803572 [TBL] [Abstract][Full Text] [Related]
38. Effects of testosterone and 7 alpha-methyl-19-nortestosterone (MENT) on sexual and aggressive behaviors in two inbred strains of male mice. Ogawa S; Robbins A; Kumar N; Pfaff DW; Sundaram K; Bardin CW Horm Behav; 1996 Mar; 30(1):74-84. PubMed ID: 8724182 [TBL] [Abstract][Full Text] [Related]
39. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. Katznelson L; Rosenthal DI; Rosol MS; Anderson EJ; Hayden DL; Schoenfeld DA; Klibanski A AJR Am J Roentgenol; 1998 Feb; 170(2):423-7. PubMed ID: 9456958 [TBL] [Abstract][Full Text] [Related]
40. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. Bhasin S; Storer TW; Berman N; Yarasheski KE; Clevenger B; Phillips J; Lee WP; Bunnell TJ; Casaburi R J Clin Endocrinol Metab; 1997 Feb; 82(2):407-13. PubMed ID: 9024227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]